🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prognostic Value of 2026 AHA/ACC Clinical Categorization in Acute Pulmonary Embolism Patients Presenting to the Emergency Department

Recruitingn/aAges 18 Years - anyAllMarmara University Pendik Training and Research H…
NCT07805616 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background: The 2026 American Heart Association/American College of Cardiology (AHA/ACC) Pulmonary Embolism Guideline (Creager et al., Circulation 2026) introduced a novel five-category (A-E) clinical classification system with subcategories and an R modifier, replacing prior risk stratification frameworks. Prospective validation of this classification system using composite clinical outcomes is lacking. Objective: To evaluate the prognostic value of the 2026 AHA/ACC clinical categorization (Categories A-E plus R modifier) for predicting 30-day Major Adverse Pulmonary Embolism Events (MAPEE) in emergency department (ED) patients with acute pulmonary embolism (PE). Methods: Prospective observational cohort study conducted at Marmara University Faculty of Medicine Emergency Department, enrolling 600 consecutive adult patients with confirmed acute PE by computed tomography (CT) pulmonary an

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age \>=18 years 2. Confirmed acute PE on CT pulmonary angiography (CTPA) within 24 hours of ED presentation 3. Informed consent obtained 4. Ability to complete 30-day follow-up Exclusion Criteria: 1. Chronic thromboembolic pulmonary hypertension (CTEPH) 2. Age \<18 years 3. Pregnancy 4. Incomplete CTPA or non-diagnostic imaging 5. Prior PE within 3 months 6. Refusal of informed consent 7. Inability to complete 30-day follow-up (no phone/address)
💊

What it tests

  • 2026 AHA/ACC Clinical Risk Categorization
📍

Where

1 site
Marmara University Pendik Training and Research Hospital
Istanbul, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy